Abuse liability of novel 'legal high' designer stimulants: Evidence from animal models

Behavioural Pharmacology

Volumn 24, Issue 5-6, 2013, Pages 341-355

  Watterson, Lucas R ^a   Watterson, Elizabeth ^a   Olive, Michael Foster ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

abuse liability; addiction; animal models; designer stimulants; piperazines; synthetic cathinones

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; CAFFEINE; CATHINONE; CENTRAL STIMULANT AGENT; COCAINE; CONTROLLED SUBSTANCE; DESIGNER DRUG; DEXAMPHETAMINE; FENFLURAMINE; ILLICIT DRUG; LYSERGIDE; METHAMPHETAMINE; METHCATHINONE; METHYLONE; MORPHINE; PIPERAZINE DERIVATIVE; PSYCHEDELIC AGENT;

AGGRESSION; AGITATION; ALERTNESS; ANXIETY; APPETITE; CONFUSION; DIZZINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG ABUSE PATTERN; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG SAFETY; DRUG SELF ADMINISTRATION; EMPATHY; EUPHORIA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HYPERTENSION; HYPERTHERMIA; INTRAVENOUS CATHETER; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PSYCHOSIS; REVIEW; SLEEP DEPRIVATION; SUBSTANCE ABUSE; TACHYCARDIA;

ANIMALS; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; SELF STIMULATION; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84881549082     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283641ec8     Document Type: Review

References (139)

1. Aarde SM, Angrish D, Barlow DJ, Wright MJ Jr, Vandewater SA, Creehan KM, et al. (2013a). Mephedrone (4-methylmethcathinone) supports intravenous self-Administration in Sprague-Dawley and Wistar rats. Addict Biol [Epub ahead of print
2. Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA (2013b). The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-Administration and locomotor activity in rats. Neuropharmacology 71:130-140
3. Ahmed SH (2010). Validation crisis in animal models of drug addiction: Beyond non-Disordered drug use toward drug addiction. Neurosci Biobehav Rev 35:172-184
4. Ahmed SH (2011). Escalation of drug use. In: Olmstead MC, editor. Animal Models of Drug Addiction, Neuromethods 53. New York, NY: Humana Press. pp. 23-67
5. Ahmed SH (2012). The science of making drug-Addicted animals. Neuroscience 211:107-125
6. Ahmed SH, Koob GF (1998). Transition from moderate to excessive drug intake: Change in hedonic set point. Science 282:298-300
7. Ahmed SH, Koob GF (1999). Long-Lasting increase in the set point for cocaine self-Administration after escalation in rats. Psychopharmacology (Berl) 146:303-312
8. Arbo MD, Bastos ML, Carmo HF (2012). Piperazine compounds as drugs of abuse. Drug Alcohol Depend 122:174-185
9. Ator NA, Griffiths RR (2003). Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70:S55-S72
10. Auerbach S, Kamalakannan N, Rutter J (1990). TFMPP and RU24969 enhance serotonin release rat hipocampus. Eur J Pharmacol 190:51-57
11. Baumann M, Ayestas M (2001). 1-(m-Chlorophenyl) piperazine (mCPP) dissociates in vivo serotonin release from long-Term serotonin depletion in rat brain. Neuropsychopharmacology 24:492-501
12. Baumann MH, Rutter JJ, Auerbach SB (1993). Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology 32: 1381-1386
13. Baumann MH, Ayestas Ma, Sharpe LG, Lewis DB, Rice KC, Rothman RB (2002). Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate. J Pharmacol Exp Ther 301:1190-1197
14. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB (2004). Effects of 'Legal X' piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci 1025:189-197
15. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB (2005). N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30:550-560
16. Baumann MH, Ayestas M, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2011). The Designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 35:192-203
17. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. (2013a). Powerful cocaine-Like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'Bath Salts' products. Neuropsychopharmacology 38:552-562
18. Baumann MH, Partilla JS, Lehner KR (2013b). Psychoactive 'bath salts': Not so soothing. Eur J Pharmacol 698:1-5
19. Ben-Shahar O, Posthunus EJ, Waldroup SA, Ettenberg A (2008). Heightened drug-seeking motivation following extended daily access to self-Administered cocaine. Prog Neuropsychopharmacol Biol Psychiatry 32:863-869
20. Bilsky E, Reid L (1991). MDL72222, a serotonin 5-HT3 receptor antagonist, blocks MDMA's ability to establish a conditioned place preference. Pharmacol Biochem Behav 39:509-512
21. Bilsky E, Hubbell C, Delconte J, Reid L (1991). MDMA produces a conditioned place preference and elicits ejaculation in male rats: A modulatory role for the endogenous opioids. Pharmacol Biochem Behav 40:443-447
22. Bilsky EJ, Hui YZ, Hubbell CL, Reid LD (1990). Methylenedioxymethamphetamine's capacity to establish place preferences and modify intake of an alcoholic beverage. Pharmacol Biochem Behav 37:633-638
23. Bardo MT, Bevins RA (2000). Conditioned place preference: What does it add to our preclinical understanding of drug reward? Psychopharmacology 153:31-43
24. Brandt SD, Sumnall HR, Measham F, Cole J (2010). Analyses of secondgeneration 'legal highs' in the UK: Initial findings. Drug Test Anal 2: 377-382
25. Brennan KA, Lake B, Hely LS, Jones K, Gittings D, Colussi-Mas J, et al. (2007). N-benzylpiperazine has characteristics of a drug of abuse. Behav Pharmacol 18:785-790
26. Cameron KN, Kolanos R, Solis E, Glennon R, De Felice LJ (2013). Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168:1750-1757
27. Carlezon WA, Chartoff EH (2007). Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2:2987-2995
28. Carroll ME, Meisch RA (2011). Acquisition of drug self-Administration. In: Olmstead MC, editor. Animal models of drug addiction, neuromethods 53. New York, NY: Humana Press. pp. 237-266
29. Carter LP, Griffiths RR (2009). Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 105:s14-s25
30. Collins RJ, Weeks JR, Cooper MM, Good PI, Russell RR (1983). Prediction of abuse liability of drugs using IV self-Administration by rats. Psychopharmacology (Berl) 82:6-13
31. Colpaert FC, Niemegeers CJE, Janssen PAJ (1976). Theoretical and methodological considerations on drug discrimination learning. Psychopharmacologia 46:169-177
32. Coppola M, Mondola R (2012). 3,4-Methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12-15
33. Cozzi N, Sievert M, Shulgin A, JacobIII P (1999). Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381:63-69
34. Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, et al. (2013). Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699:180-187
35. Cunningham C, Noble D (2006). Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug. Ann N Y Acad Sci 654:431-433
36. Cunningham C, Groblewski P, Voorhees C (2011). Place conditioning. In: Olmstead MC, editor. Animal models of drug addiction, neuromethods 53. New York, NY: Humana Press. pp. 167-190
37. Dal Cason TA, Young R, Glennon R (1997). Cathinone: An investigation of several N-Alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav 58:1109-1116
38. De Boer D, Bosman IJ, Hidvégi E, Manzoni C, Benkö AA, Dos Reys LJ, Maes R (2001). Piperazine-Like compounds: A new group of designer drugs-of-Abuse on the European market. Forensic Sci Int 121:47-56
39. De La Garza R, Fabrizio KR, Gupta A (2007). Relevance of rodent models of intravenous MDMA self-Administration to human MDMA consumption patterns. Psychopharmacology (Berl) 189:425-434
40. Drug Enforcement Administration, United States Department of Justice (2002). Drug scheduling actions-2002-Temporary placement of benzylpiperazine and trifluoromethylphenylpiperazine into schedule I. Available at: Http:// www.deadiversion.usdoj.gov/fed-regs/rules/2002/fr09202.htm [Accessed 1 February 2013
41. Drug Enforcement Administration, United States Department of Justice (2011a). Chemicals used in 'bath salts', now under federal control and regulation. Available at: Http://www.justice.gov/dea/pubs/pressrel/pr102111.html [Accessed 21 October 21
42. Drug Enforcement Administration, United States Department of Justice (2011b). Synthetic cathinones-DEA request for informationAvailable at: Http:// www.justice.gov/dea/pr/micrograms/2011/mg0411.pdf [Accessed 1 February 2013
43. Drug Enforcement Administration, United States Department of Justice (2011c). Background, data and analysis of synthetic cathinones: Mephedrone (4-MMC), methylone (MDMC) and 3,4-methylenedioxypyrovalerone (mdpv). Available at: Http://www.deadiversion.usdoj.gov/fed-regs/rules/2011/HHS% PDF/background.pdf [Accessed 1 February 2013
44. Drug Enforcement Administration, United States Department of Justice (2012a). Scheduling actions-Alphabetical order. 811:1-7. Available at: Http://www. deadiversion.usdoj.gov/schedules/orangebook/a-sched-alpha.pdf [Accessed 1 February 2013
45. Drug Enforcement Administration, United States Department of Justice (2012b). Schedules of controlled substances: Extension of temporary placement of methylone into schedule I of the Controlled Substances Act. Final order. Available at: Http://www.deadiversion.usdoj.gov/fed-regs/rules/2012/fr1018- 11.htm [Accessed 1 February 2013
46. Drug Enforcement Administration, United States Department of Justice (2013). Synthetic cannabinoids and cathinones-DEA request for information. Available at: Http://www.cpdd.vcu.edu/Pages/Links/Links-PDFs/SYNTHETIC% 20CATHINONES.pdf [Accessed 22 January 2013
47. Elliott S (2011). Current awareness of piperazines: Pharmacology and toxicology. Drug Test Anal 3:430-438
48. Eriksson E, Engberg G, Bing O, Nissbrandt H (1999). Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 20:287-296
49. Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A (2005). Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 77:161-168
50. Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC (2013). In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: Drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38:563-573
51. Farre M, Cami J (1991). Pharmacokinetic consideration in abuse liability evaluation. Br J Addict 12:1601-1606
52. Fass JA, Fass AD, Garcia AS (2012). Synthetic cathinones (bath salts): Legal status and patterns of abuse. Annal Pharmacother 46:436-441
53. Ferrario CR, Gorny G, Crombag HS, Li Y, Kolb B, Robinson TE (2005). Neural and behavioral plasticity associated with the transition from controlled to escalated cocaine use. Biol Psychiatry 9:751-759
54. Gardner EL (2010).What we have learned about addiction from animal models of drug self-Administration. Am J Addict 9:285-313
55. Gass JT, Osborne MPH, Watson NL, Brown JL, Olive MF (2008). mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology 34:820-833
56. Gipson CD, Bardo MT (2009). Extended access to amphetamine selfadministration increases impulsive choice in a delay discounting task in rats. Psychopharmacology (Berl) 3:391-400
57. Griffiths R, Brady J, Bradford L (1979). Predicting the abuse liability of drugs with animal drug self-Administration procedures: Psychomotor stimulants and hallucinogens. In: Thompson T, Dews PB, editors. Adv Behav Pharmacol. 2nd ed. New York: Academic Press. pp. 164-200
58. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al. (2011). 4-Methylmethcathinone(mephedrone): Neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536
59. Hillebrand J, Olszewski D, Sedefov R (2010). Legal highs on the Internet. Subst Use Misuse 45:330-340
60. Howell LL, Fantegrossi WE (2009). Chapter 9: Intravenous drug self-Administration in nonhuman primates. In: Buccafusco JJ, editor. Methods of behavioral analysis in neuroscience. 2nd ed. Boca Raton, FL: CRC Press
61. Hubner C, Bird M, Rassnick S (1988). The threshold lowering effects of MDMA (ecstasy) on brain-stimulation reward. Psychopharmacology (Berl) 95: 49-51
62. Huston JP, de Souza Silva MA, Topic B, Muller P (2013). What's conditioned in conditioned place preference? Trends Pharmacol Sci 34:162-166
63. Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, Russell BR (2010). Determining the subjective effects of TFMPP in human males. Psychopharmacology (Berl) 211:347-353
64. Jansen KL (1999). Ecstasy (MDMA) dependence. Drug Alcohol Depend 53:121-124
65. Kalix P, Khan I (1984). Khat: An amphetamine-Like plant material. Bull World Health Organ 62:681
66. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, Yoshitake T (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164:1949-1958
67. Kelly JP (2011). Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Test Anal 3:439-453
68. Knackstedt LA, Kalivas PW (2007). Extended access to cocaine self-Administration enhances drug-primed reinstatement but not behavioral sensitization. J Pharmacol Exp Ther 322:1103-1109
69. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, et al. (2004). Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 27:739-749
70. Kornetsky C, Esposito R (1979). Euphorigenic drugs: Effects on the reward pathways of the brain. Fed Proc 38:2473-2476
71. Kornetsky C, Esposito RU, McLean S, Jacobson JO (1979). Intracranial selfstimulation thresholds: A model for the hedonic effects of drugs of abuse. Arch Gen Psychiatry 36:289-292
72. Leri F, Franklin KB (2000). Effects of diazepam on conditioned place preference induced by morphine or amphetamine in the rat. Psychopharmacology (Berl) 150:351-360
73. Lin D, Koob GF, Markou A (1999). Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat-interactions between the two drugs. Psychopharmacology (Berl) 145:283-294
74. Lin HQ, Jackson DM, Atrens DM, Christie MJ, McGregor IS (1997). Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal selfstimulation. Brain Res 744:351-357
75. Lin JC, Bangs N, Lee H, Kydd RR, Russell BR (2009). Determining the subjective and physiological effects of BZP on human females. Psychopharmacology (Berl) 207:439-446
76. Lin JC, Jan RK, Lee H, Jensen M-A, Kydd RR, Russell BR (2011). Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology (Berl) 214:761-768
77. Lisek R, Xu W, Yuvasheva E, Chiu Y-T, Reitz AB, Liu-Chen L-Y, Rawls SM (2012). Mephedrone (bath salt) elicits conditioned place preference and dopaminesensitive motor activation. Drug Alcohol Depend 126:257-262
78. López-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012). Comparative neuropharmacology of three psychostimulant cathinone derivatives: Butylone, mephedrone and methylone. Br J Pharmacol 167:407-420
79. Madras BK (2012). Designer drugs: An escalating public health challenge. J Global Drug Policy Pract 6:1-57
80. Manghi RA, Broers B, Khan R, Benguettat D, Khazaal Y, Zullino DF (2009). Khat use: Lifestyle or addiction? J Psychoactive Drugs 41:1-10
81. Markou A, Koob GF (1992). Construct validity of a self-stimulation threshold paradigm: Effects of reward and performance manipulations. Physiol Behav 51:111-119
82. Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J (2012). Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22:231-236
83. Mas-Morey P, Visser MHM, Winkelmolen L, Touw DJ (2012). Clinical toxicology and management of intoxications with synthetic cathinones (bath salts). J Pharm Prac [Epub ahead of print
84. Meisch RA (1987). Factors controlling drug reinforced behavior. Pharmacol Biochem Behav 27:367-371
85. Meltzer PC, Butler D, Deschamps JR, Madras BK (2006). 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J Med Chem 49:1420-1432
86. Meririnne E, Kajos M, Kankaanpää A, Seppä lä T (2006). Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin Pharmacol Toxicol 98:346-350
87. Miliaressis E, Rompre PP, Laviolette P, Philippe L, Coulombe D (1986). The curve-shift paradigm in self-stimulation. Physiol Behav 37:85-91
88. Miyazawa M, Kojima T, Nakaji S (2011). Behavioral and rewarding effects of methylone, an analog of MDMA in mice. Hirosaki Med J 62:56-71
89. Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS (2012). Mephedrone (4-methylmethcathinone, 'meow'): Acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 17:409-422
90. Nagai F, Nonaka R, Satoh HK (2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132-137
91. National Drug Intelligence Center, United States Department of Justice (2011). Synthetic cathinones (bath salts): An emerging domestic threat. Available at: Http://www.justice.gov/archive/ndic/pubs44/44571/44571p.pdf [Accessed 1 February 2013
92. Nikolova I, Danchev N (2008). Piperazine based substances of abuse: A new party pills on Bulgarian drug market. Biotechnol Biotechnolog Equip 22: 652-655
93. Olds J (1962). Hypothalamic substrates of reward. Physiol Rev 42:554-604
94. Olds J, Milner P (1954). Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47:419-427
95. One Hundred Twelfth Congress of the United States of America (2012). S. 3187: Food and Drug Administration Safety and Innovation Act. An Act to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user fee programs for generic drugs and biosimilars, and for other purposes. Second Session, Begun and held at the City of Washington, 3 January 2012. Available at: Http://www.gpo.gov/fdsys/pkg/BILLS-112s3187enr/pdf/BILLS-112s3187enr.pdf [Accessed 1 February 2013
96. O'Brien CP, Gardner EL (2005). Critical assessment of how to study addiction and its treatment: Human and non-human animal models. Pharmacol Ther 108:18-58
97. O'Connor EC, Chapman K, Butler P, Mead AN (2011). The predictive validity of the rat self-Administration model for abuse liability. Neurosci Biobehav Rev 35:912-938
98. O'dell LE, Chen SA, Smith RT, Specio SE, Balster RL, Paterson NE, et al. (2007). Extended access to nicotine self-Administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther 320:180-193
99. Panlilio LV (2011). Stimulant self-Administration. In: Olmstead MC, editor. Animal models of drug addiction, neuromethods 53. 3: New York, NY: Humana Press. pp. 57-81
100. Panlilio LV, Goldberg SR (2007). Self-Administration of drugs in animals and humans as a model and investigative tool. Addiction 12:1863-1870
101. Pettibone DJ, Williams M (1984). Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 33:1531-1535
102. Prosser JM, Nelson LS (2011). The toxicology of bath salts: A review of synthetic cathinones. J Med Toxicol 8:33-42
103. Ramsey J, Dargan PI, Smyllie M, Davies S, Button J, Holt DW,Wood DM (2010). Buying 'legal' recreational drugs does not mean that you are not breaking the law. QJM 103:777-783
104. Redgrave P, Dean P (1981). Intracranial self-stimulation. Br Med Bull 37:141-146
105. Richardson NR, Roberts DC (1996). Progressive ratio schedules in drug selfadministration studies in rats: A method to evaluate reinforcing efficacy. J Neurosci Methods 66:1-11
106. Robinson JE, Agoglia AE, Fish EW, Krouse MC, Malanga CJ (2012). Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: Comparison to cocaine. Behav Brain Res 234:76-81
107. Robledo P, Balerio G, Berrendero F, Maldonado R (2004). Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn Schmiedebergs Arch Pharmacol 369:338-349
108. Rosenbaum CD, Carreiro SP, Babu KM (2012). Here today, gone tomorrowyand back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), Kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 8:15-32
109. Rothman RB, Baumann MH (2003). Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479:23-40
110. Rothman RB, Baumann MH (2006). Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-Type drugs. Ann N Y Acad Sci 1074:245-260
111. Salzmann J, Marie-Claire C, Le Guen S, Roques BP, Noble F (2003). Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice. Br J Pharmacol 140:831-838
112. Sanchis-Segura C, Spanagel R (2006). Behavioural assessment of drug reinforcement and addictive features in rodents: An overview. Addict Biol 11:2-38
113. Schechter MD (1991). Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination. Pharmacol Biochem Behav 38:539-544
114. Schenk S (2009). MDMA self-Administration in laboratory animals: A summary of the literature and proposal for future research. Neuropsychobiology 60: 130-136
115. Schenk S, Gittings D, Johnstone M, Daniela E (2003). Development, maintenance and temporal pattern of self-Administration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 169:21-27
116. Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC (2007). MDMA selfadministration in rats: Acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci 26:3229-3236
117. Schoeffter P, Hoyer D (1989). Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: Do discriminatory 5-HT1B receptor ligands exist? Naunyn Schmiedebergs Arch Pharmacol 339:675-683
118. Schuster CR, Thompson T (1969). Self administration of and behavioral dependence on drugs. Annu Rev Pharmacol 9:483-502
119. Shanks KG, Dahn T, Behonick G, Terrell A (2012). Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 36:360-371
120. Shippenberg TS, Koob GF (2002). Recent advances in animal models of drug addiction. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: The fifth generation of progress. Philadelphia, Pennsylvania: Lippincott Williams and Wilkins. pp. 1381-1397
121. Simmler L, Buser T, Donzelli M, Schramm Y, Dieu L-H, Huwyler J, et al. (2013). Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458-470
122. Skinner BF (1938). The behavior of organisms. New York: Appleton-Century-Crofts
123. Spiller HA, Ryan ML,Weston RG, Jansen J (2011). Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin Toxicol 49:499-505
124. Stafford D, LeSage MG, Glowa JR (1998). Progressive-ratio schedules of drug delivery in the analysis of drug self-Administration: A review. Psychopharmacology (Berl) 139:169-184
125. Tancer ME, Johanson CE (2001). The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65:97-101
126. Thomsen M, Caine SB (2007). Intravenous drug self-Administration in mice: Practical considerations. Behav Genet 37:101-118
127. Tzschentke TM (1998). Measuring reward with the conditioned place preference paradigm: A comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56:613-672
128. Tzschentke TM (2007). Measuring reward with the conditioned place preference (CPP) paradigm: Update of the last decade. Addict Biol 12:227-462
129. Vardakou I, Pistos C, Spiliopoulou C (2011). Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 201:191-195
130. Varner KJ, Daigle K, Weed PF, Lewis PB, Mahne SE, Sankaranarayanan A, Winsauer PJ (2013). Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology (Berl) 225:675-685
131. Vlachou S, Markou A (2011). Intracranial self-stimulation. In: Olmstead MC, editor. Animal models of drug addiction, neuromethods 53. New York, NY: Humana Press. pp. 3-56
132. Watterson LR, Hood LE, Sewalia K, Tomek SE, Yahn S, Johnson CT, et al. (2012). The reinforcing and rewarding effects of methylone, a synthetic cathinone commonly found in 'bath salts'. J Addic Res Ther S9:1-8
133. Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, et al. (2013). Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol [Epub ahead of print
134. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE,Woolverton WL (2005). Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848-854
135. Wolf W, Kuhn D (1991). The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP. Neurochem Int 19:39-44
136. Yarosh HL, Katz EB, Coop A, Fantegrossi WE (2007). MDMA-Like behavioral effects of N-substituted piperazines in the mouse. Pharmacol Biochem Behav 88:18-27
137. Yeap CW, Bian CK, Fahmi A, Abdullah L (2010). A review on benzylpiperazine and trifluoromethylphenypiperazine: Origins, effects, prevalence and legal status. Health Environ J 1:38-50
138. Yokel RA, Pickens R (1973). Self-Administration of optical isomers of amphetamine and methylamphetamine by rats. J Pharmacol Exp Ther 187:27-33
139. Young R (2001). Drug Discrimination. In: Buccafusco J, editor. Methods of behavior analysis in neuroscience. 1st ed. Boca Raton, FL: CRC Press. pp. 86-95